Digital Content 
NEWS #PharmaBuzz
15 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/15/3062116/0/en/Cardiff-Oncology-Announces-Completion-of-Enrollment-in-Phase-2-CRDF-004-Trial-Evaluating-Onvansertib-for-the-Treatment-of-First-line-RAS-mutated-Metastatic-Colorectal-Cancer.html
01 Mar 2024
// Ayisha Sharma ENDPTS
https://endpts.com/cardiff-teases-plk1-inhibitor-efficacy-in-colorectal-cancer-ahead-of-first-line-readout/
12 Sep 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-plans-for-a-randomized-trial-in-metastatic-colorectal-cancer-mcrc-durability-of-responses-in-ongoing-phase-1b2-trial-in-mcrc-and-additional-business-updates-301622266.html
11 Sep 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-new-preclinical-and-clinical-data-from-program-in-kras-mutated-metastatic-colorectal-cancer-mcrc-at-the-esmo-congress-2022-301621536.html
08 Apr 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-data-showing-the-combination-of-parp-inhibition-with-onvansertib-overcomes-parp-inhibitor-resistance-in-brca1-mutant-and-wildtype-patient-derived-xenograft-ovarian-cancer-models-301520694.html
https://cardiffoncology.investorroom.com/2022-01-18-Cardiff-Oncology-Announces-New-Data-from-Lead-Clinical-Program-in-KRAS-mutated-Metastatic-Colorectal-Cancer-Showing-Robust-Objective-Response-Rate-and-Progression-Free-Survival
Share 